Full metadata record

DC FieldValueLanguage
dc.contributor.author노은주-
dc.contributor.author모하메드 햄디-
dc.contributor.authorAhmed Elkamhawy-
dc.contributor.authorHossam Nada-
dc.contributor.authorMagda H. Abdellattif-
dc.contributor.author이경-
dc.date.accessioned2021-09-07T15:30:01Z-
dc.date.available2021-09-07T15:30:01Z-
dc.date.issued2021-09-
dc.identifier.citationVOL 9-1150-
dc.identifier.issn2227-9059-
dc.identifier.other57313-
dc.identifier.urihttp://pubs.kist.re.kr/handle/201004/73750-
dc.description.abstractAlthough the sea ecosystem offers a broad range of bioactivities including anticancer, none of the FDA-approved antiproliferative protein kinase inhibitors are derived from a marine source. In a step to develop new marine-inspired potent kinase inhibitors with antiproliferative activities, a new series of hybrid small molecules (5a?5g) was designed and synthesized based on chemical moieties derived from two marine natural products (Meridianin E and Leucettamine B). Over a panel of 14 cancer-related kinases, a single dose of 10 ?M of the parent hybrid 5a possessing the benzo[d][1,3]dioxole moiety of Leucettamine B was able to inhibit the activity of FMS, LCK, LYN, and DAPK1 kinases with 82.5 ± 0.6, 81.4 ± 0.6, 75.2 ± 0.0, and 55 ± 1.1%, respectively. Further optimization revealed the most potent multiple kinase inhibitor of this new series (5g) with IC50 values of 110, 87.7, and 169 nM against FMS, LCK, and LYN kinases, respectively. Compared to imatinib (FDA-approved multiple kinase inhibitor), compound 5g was found to be ~ 9- and 2-fold more potent than imatinib over both FMS and LCK kinases, respectively. In silico docking simulation models of the synthesized compounds within the active site of FMS, LCK, LYN, and DAPK1 kinases offered reasonable explanations of the elicited biological activities. In an in vitro anticancer assay using a library of 60 cancer cell lines that include blood, lung, colon, CNS, skin, ovarian, renal, prostate, and breast cancers, it was found that compound 5g was able to suppress 60 and 70% of tumor growth in leukemia SR and renal RXF 393 cell lines, respectively. Moreover, an ADME study indicated a suitable profile of compound 5g concerning cell permeability and blood-brain barrier (BBB) impermeability, avoiding possible CNS side effects. Accordingly, compound 5g is reported as a potential lead towards novel antiproliferative marine-derived kinase modulators.-
dc.publisherBiomedicines-
dc.subject천연물 유래-
dc.subject저분자 화합물-
dc.subjectmulti kinase-
dc.subject항암활성-
dc.titleDevelopment of New Meridianin/Leucettine-Derived Hybrid Small molecules as nanomolar multi kinase inhibitors with antitumor activity-
dc.typeArticle-
dc.relation.page11311150-
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE